1x78 › Citations

Structure-based design of estrogen receptor-beta selective ligands.

Manas ES, Unwalla RJ, Xu ZB, Malamas MS, Miller CP, Harris HA, Hsiao C, Akopian T, Hum WT, Malakian K, Wolfrom S, Bapat A, Bhat RA, Stahl ML, Somers WS, Alvarez JC
J Am Chem Soc 126 15106-19 (2004)
Related entries: 1u9e, 1x76, 1x7b, 1x7e

Cited: 79 times
EuropePMC logo PMID: 15548008

Abstract

We present the structure-based optimization of a series of estrogen receptor-beta (ERbeta) selective ligands. X-ray cocrystal structures of these ligands complexed to both ERalpha and ERbeta are described. We also discuss how molecular modeling was used to take advantage of subtle differences between the two binding cavities in order to optimize selectivity for ERbeta over ERalpha. Quantum chemical calculations are utilized to gain insight into the mechanism of selectivity enhancement. Despite only two relatively conservative residue substitutions in the ligand binding pocket, the most selective compounds have greater than 100-fold selectivity for ERbeta relative to ERalpha when measured using a competitive radioligand binding assay.

Articles - 1x78 mentioned but not cited (5)

  1. Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling. Leung YK, Mak P, Hassan S, Ho SM. Proc Natl Acad Sci U S A 103 13162-13167 (2006)
  2. A molecular docking study of phytochemical estrogen mimics from dietary herbal supplements. Powers CN, Setzer WN. In Silico Pharmacol 3 4 (2015)
  3. In silico prediction of estrogen receptor subtype binding affinity and selectivity using statistical methods and molecular docking with 2-arylnaphthalenes and 2-arylquinolines. Wang Z, Li Y, Ai C, Wang Y. Int J Mol Sci 11 3434-3458 (2010)
  4. Selective ligands of estrogen receptor β discovered using pharmacophore mapping and structure-based virtual screening. Chen L, Wu D, Bian HP, Kuang GL, Jiang J, Li WH, Liu GX, Zou SE, Huang J, Tang Y. Acta Pharmacol Sin 35 1333-1341 (2014)
  5. Insights from molecular network analysis to docking of sterubin with potential targets. Viswanathan S, Subramanian K, Ramesh V, Vasanthi AHR. Bioinformation 19 1184-1192 (2023)


Reviews citing this publication (19)

  1. Estrogen receptors: how do they signal and what are their targets. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Ström A, Treuter E, Warner M, Gustafsson JA. Physiol Rev 87 905-931 (2007)
  2. A medicinal chemist's guide to molecular interactions. Bissantz C, Kuhn B, Stahl M. J Med Chem 53 5061-5084 (2010)
  3. Structure-function relationship of estrogen receptor alpha and beta: impact on human health. Ascenzi P, Bocedi A, Marino M. Mol Aspects Med 27 299-402 (2006)
  4. Structural overview of the nuclear receptor superfamily: insights into physiology and therapeutics. Huang P, Chandra V, Rastinejad F. Annu Rev Physiol 72 247-272 (2010)
  5. Reflections on the discovery and significance of estrogen receptor beta. Koehler KF, Helguero LA, Haldosén LA, Warner M, Gustafsson JA. Endocr Rev 26 465-478 (2005)
  6. The nuclear receptor superfamily and drug discovery. Moore JT, Collins JL, Pearce KH. ChemMedChem 1 504-523 (2006)
  7. Estrogen receptor β ligands: recent advances and biomedical applications. Minutolo F, Macchia M, Katzenellenbogen BS, Katzenellenbogen JA. Med Res Rev 31 364-442 (2011)
  8. Understanding nuclear receptor form and function using structural biology. Rastinejad F, Huang P, Chandra V, Khorasanizadeh S. J Mol Endocrinol 51 T1-T21 (2013)
  9. Estrogen and progesterone receptors: from molecular structures to clinical targets. Ellmann S, Sticht H, Thiel F, Beckmann MW, Strick R, Strissel PL. Cell Mol Life Sci 66 2405-2426 (2009)
  10. Lessons learnt from structural studies of the oestrogen receptor. Pike AC. Best Pract Res Clin Endocrinol Metab 20 1-14 (2006)
  11. Selectively targeting estrogen receptors for cancer treatment. Shanle EK, Xu W. Adv Drug Deliv Rev 62 1265-1276 (2010)
  12. Regulation of specific target genes and biological responses by estrogen receptor subtype agonists. Leitman DC, Paruthiyil S, Vivar OI, Saunier EF, Herber CB, Cohen I, Tagliaferri M, Speed TP. Curr Opin Pharmacol 10 629-636 (2010)
  13. Bioactivation of Selective Estrogen Receptor Modulators (SERMs). Dowers TS, Qin ZH, Thatcher GR, Bolton JL. Chem Res Toxicol 19 1125-1137 (2006)
  14. Versatility or promiscuity: the estrogen receptors, control of ligand selectivity and an update on subtype selective ligands. Ng HW, Perkins R, Tong W, Hong H. Int J Environ Res Public Health 11 8709-8742 (2014)
  15. Structural and Functional Diversity of Estrogen Receptor Ligands. Farooq A. Curr Top Med Chem 15 1372-1384 (2015)
  16. Receptor-Receptor Interactions as a Widespread Phenomenon: Novel Targets for Drug Development? Guidolin D, Marcoli M, Tortorella C, Maura G, Agnati LF. Front Endocrinol (Lausanne) 10 53 (2019)
  17. Recent applications of protein crystallography and structure-guided drug design. Williams SP, Kuyper LF, Pearce KH. Curr Opin Chem Biol 9 371-380 (2005)
  18. Estrogen receptor beta selective nonsteroidal estrogens: seeking clinical indications. Mohler ML, Narayanan R, Coss CC, Hu K, He Y, Wu Z, Hong SS, Hwang DJ, Miller DD, Dalton JT. Expert Opin Ther Pat 20 507-534 (2010)
  19. How technical progress reshaped behavioral neuroendocrinology during the last 50 years… and some methodological remarks. Balthazart J. Horm Behav 118 104682 (2020)

Articles citing this publication (55)

  1. Selective estrogen receptor-beta agonists repress transcription of proinflammatory genes. Cvoro A, Tatomer D, Tee MK, Zogovic T, Harris HA, Leitman DC. J Immunol 180 630-636 (2008)
  2. Genome-wide dynamics of chromatin binding of estrogen receptors alpha and beta: mutual restriction and competitive site selection. Charn TH, Liu ET, Chang EC, Lee YK, Katzenellenbogen JA, Katzenellenbogen BS. Mol Endocrinol 24 47-59 (2010)
  3. Understanding the selectivity of genistein for human estrogen receptor-beta using X-ray crystallography and computational methods. Manas ES, Xu ZB, Unwalla RJ, Somers WS. Structure 12 2197-2207 (2004)
  4. Bisphenol AF is a full agonist for the estrogen receptor ERalpha but a highly specific antagonist for ERbeta. Matsushima A, Liu X, Okada H, Shimohigashi M, Shimohigashi Y. Environ Health Perspect 118 1267-1272 (2010)
  5. Confidence limits, error bars and method comparison in molecular modeling. Part 1: the calculation of confidence intervals. Nicholls A. J Comput Aided Mol Des 28 887-918 (2014)
  6. Estrogen Receptor β Activation Rapidly Modulates Male Sexual Motivation through the Transactivation of Metabotropic Glutamate Receptor 1a. Seredynski AL, Balthazart J, Ball GF, Cornil CA. J Neurosci 35 13110-13123 (2015)
  7. ERbeta ligands. Part 4: Synthesis and structure-activity relationships of a series of 2-phenylquinoline derivatives. Vu AT, Cohn ST, Manas ES, Harris HA, Mewshaw RE. Bioorg Med Chem Lett 15 4520-4525 (2005)
  8. Synthesis and crystal structure of a phosphorylated estrogen receptor ligand binding domain. Möcklinghoff S, Rose R, Carraz M, Visser A, Ottmann C, Brunsveld L. Chembiochem 11 2251-2254 (2010)
  9. Isocoumarins as estrogen receptor beta selective ligands: Isomers of isoflavone phytoestrogens and their metabolites. De Angelis M, Stossi F, Waibel M, Katzenellenbogen BS, Katzenellenbogen JA. Bioorg Med Chem 13 6529-6542 (2005)
  10. Identification by Molecular Docking ofHomoisoflavones from Leopoldia comosa as Ligands of Estrogen Receptors. Grande F, Rizzuti B, Occhiuzzi MA, Ioele G, Casacchia T, Gelmini F, Guzzi R, Garofalo A, Statti G. Molecules 23 E894 (2018)
  11. ERbeta ligands. Part 6: 6H-Chromeno[4,3-b]quinolines as a new series of estrogen receptor beta-selective ligands. Vu AT, Campbell AN, Harris HA, Unwalla RJ, Manas ES, Mewshaw RE. Bioorg Med Chem Lett 17 4053-4056 (2007)
  12. Linkage effects on binding affinity and activation of GPR30 and estrogen receptors ERalpha/beta with tridentate pyridin-2-yl hydrazine tricarbonyl-Re/(99m)Tc(I) chelates. Ramesh C, Bryant B, Nayak T, Revankar CM, Anderson T, Carlson KE, Katzenellenbogen JA, Sklar LA, Norenberg JP, Prossnitz ER, Arterburn JB. J Am Chem Soc 128 14476-14477 (2006)
  13. Benzopyrans as selective estrogen receptor beta agonists (SERBAs). Part 4: functionalization of the benzopyran A-ring. Norman BH, Richardson TI, Dodge JA, Pfeifer LA, Durst GL, Wang Y, Durbin JD, Krishnan V, Dinn SR, Liu S, Reilly JE, Ryter KT. Bioorg Med Chem Lett 17 5082-5085 (2007)
  14. Estrogen receptor beta-selective agonists stimulate calcium oscillations in human and mouse embryonic stem cell-derived neurons. Zhang L, Blackman BE, Schonemann MD, Zogovic-Kapsalis T, Pan X, Tagliaferri M, Harris HA, Cohen I, Pera RA, Mellon SH, Weiner RI, Leitman DC. PLoS One 5 e11791 (2010)
  15. Androstenediol analogs as ER-beta-selective SERMs. Blizzard TA, Gude C, Morgan JD, Chan W, Birzin ET, Mojena M, Tudela C, Chen F, Knecht K, Su Q, Kraker B, Mosley RT, Holmes MA, Sharma N, Fitzgerald PM, Rohrer SP, Hammond ML. Bioorg Med Chem Lett 16 834-838 (2006)
  16. Selectivity of natural, synthetic and environmental estrogens for zebrafish estrogen receptors. Pinto C, Grimaldi M, Boulahtouf A, Pakdel F, Brion F, Aït-Aïssa S, Cavaillès V, Bourguet W, Gustafsson JA, Bondesson M, Balaguer P. Toxicol Appl Pharmacol 280 60-69 (2014)
  17. 3D models of MBP, a biologically active metabolite of bisphenol A, in human estrogen receptor α and estrogen receptor β. Baker ME, Chandsawangbhuwana C. PLoS One 7 e46078 (2012)
  18. Estrogen receptor ligands: design and synthesis of new 2-arylindene-1-ones. McDevitt RE, Malamas MS, Manas ES, Unwalla RJ, Xu ZB, Miller CP, Harris HA. Bioorg Med Chem Lett 15 3137-3142 (2005)
  19. Identification of xenoestrogens in food additives by an integrated in silico and in vitro approach. Amadasi A, Mozzarelli A, Meda C, Maggi A, Cozzini P. Chem Res Toxicol 22 52-63 (2009)
  20. Aerobic iron-based cross-dehydrogenative coupling enables efficient diversity-oriented synthesis of coumestrol-based selective estrogen receptor modulators. Kshirsagar UA, Parnes R, Goldshtein H, Ofir R, Zarivach R, Pappo D. Chemistry 19 13575-13583 (2013)
  21. The unexpected science of estrogen receptor-beta selective agonists: a new class of anti-inflammatory agents? Harris HA. Nucl Recept Signal 4 e012 (2006)
  22. Discovery of natural estrogen receptor modulators with structure-based virtual screening. Cao X, Jiang J, Zhang S, Zhu L, Zou J, Diao Y, Xiao W, Shan L, Sun H, Zhang W, Huang J, Li H. Bioorg Med Chem Lett 23 3329-3333 (2013)
  23. Treatment with an orally bioavailable prodrug of 17β-estradiol alleviates hot flushes without hormonal effects in the periphery. Merchenthaler I, Lane M, Sabnis G, Brodie A, Nguyen V, Prokai L, Prokai-Tatrai K. Sci Rep 6 30721 (2016)
  24. A synthesis strategy for tetracyclic terpenoids leads to agonists of ERβ. Kim WS, Shalit ZA, Nguyen SM, Schoepke E, Eastman A, Burris TP, Gaur AB, Micalizio GC. Nat Commun 10 2448 (2019)
  25. Application of screening methods, shape signatures and engineered biosensors in early drug discovery process. Hartman I, Gillies AR, Arora S, Andaya C, Royapet N, Welsh WJ, Wood DW, Zauhar RJ. Pharm Res 26 2247-2258 (2009)
  26. Estrogen receptor ligands. Part 13: Dihydrobenzoxathiin SERAMs with an optimized antagonist side chain. Blizzard TA, DiNinno F, Chen HY, Kim S, Wu JY, Chan W, Birzin ET, Yang YT, Pai LY, Hayes EC, DaSilva CA, Rohrer SP, Schaeffer JM, Hammond ML. Bioorg Med Chem Lett 15 3912-3916 (2005)
  27. Characterization of the oestrogenic activity of non-aromatic steroids: are there male-specific endogenous oestrogen receptor modulators? Wang P, Wen Y, Han GZ, Sidhu PK, Zhu BT. Br J Pharmacol 158 1796-1807 (2009)
  28. Computational polypharmacology analysis of the heat shock protein 90 interactome. Anighoro A, Stumpfe D, Heikamp K, Beebe K, Neckers LM, Bajorath J, Rastelli G. J Chem Inf Model 55 676-686 (2015)
  29. A-C Estrogens as Potent and Selective Estrogen Receptor-Beta Agonists (SERBAs) to Enhance Memory Consolidation under Low-Estrogen Conditions. Hanson AM, Perera KLIS, Kim J, Pandey RK, Sweeney N, Lu X, Imhoff A, Mackinnon AC, Wargolet AJ, Van Hart RM, Frick KM, Donaldson WA, Sem DS. J Med Chem 61 4720-4738 (2018)
  30. Characterization of the estradiol-binding site structure of human pancreas-specific protein disulfide isomerase: indispensable role of the hydrogen bond between His278 and the estradiol 3-hydroxyl group. Fu XM, Wang P, Zhu BT. Biochemistry 50 106-115 (2011)
  31. ERbeta ligands. Part 5: synthesis and structure-activity relationships of a series of 4'-hydroxyphenyl-aryl-carbaldehyde oxime derivatives. Mewshaw RE, Bowen SM, Harris HA, Xu ZB, Manas ES, Cohn ST. Bioorg Med Chem Lett 17 902-906 (2007)
  32. Specific activation of estrogen receptor alpha and beta enhances male sexual behavior and neuroplasticity in male Japanese quail. Seredynski AL, Ball GF, Balthazart J, Charlier TD. PLoS One 6 e18627 (2011)
  33. Bridged androstenediol analogs as ER-beta selective SERMs. Blizzard TA, Gude C, Chan W, Birzin ET, Mojena M, Tudela C, Chen F, Knecht K, Su Q, Kraker B, Holmes MA, Rohrer SP, Hammond ML. Bioorg Med Chem Lett 17 2944-2948 (2007)
  34. Multiple-targeting and conformational selection in the estrogen receptor: computation and experiment. Yuan P, Liang K, Ma B, Zheng N, Nussinov R, Huang J. Chem Biol Drug Des 78 137-149 (2011)
  35. Discovery of novel SERMs with a ferrocenyl entity based on the oxabicyclo[2.2.1]heptene scaffold and evaluation of their antiproliferative effects in breast cancer cells. Zheng Y, Wang C, Li C, Qiao J, Zhang F, Huang M, Ren W, Dong C, Huang J, Zhou HB. Org Biomol Chem 10 9689-9699 (2012)
  36. Interaction force diagrams: new insight into ligand-receptor binding. Shadnia H, Wright JS, Anderson JM. J Comput Aided Mol Des 23 185-194 (2009)
  37. Naturally occurring plant-based anticancerous candidates as prospective ABCG2 inhibitors: an in silico drug discovery study. Ibrahim MAA, Abdelrahman AHM, Badr EAA, Almansour NM, Alzahrani OR, Ahmed MN, Soliman MES, Naeem MA, Shawky AM, Sidhom PA, Mekhemer GAH, Atia MAM. Mol Divers 26 3255-3277 (2022)
  38. Structural characterization of the binding interactions of various endogenous estrogen metabolites with human estrogen receptor α and β subtypes: a molecular modeling study. Wang P, McInnes C, Zhu BT. PLoS One 8 e74615 (2013)
  39. Synthesis and anticancer cell potential of steroidal 16,17-seco-16,17a-dinitriles: identification of a selective inhibitor of hormone-independent breast cancer cells. Nikolić AR, Petri ET, Klisurić OR, Ćelić AS, Jakimov DS, Djurendić EA, Penov Gaši KM, Sakač MN. Bioorg Med Chem 23 703-711 (2015)
  40. Synthesis and evaluation of aryl-substituted diarylpropionitriles, selective ligands for estrogen receptor beta, as positron-emission tomographic imaging agents. Moon BS, Carlson KE, Katzenellenbogen JA, Choi TH, Chi DY, Kim JY, Cheon GJ, Koh HY, Lee KC, An G. Bioorg Med Chem 17 3479-3488 (2009)
  41. Estrogen receptor beta ligands: design and synthesis of new 2-phenyl-isoindole-1,3-diones. Ullrich JW, Unwalla RJ, Singhaus RR, Harris HA, Mewshaw RE. Bioorg Med Chem Lett 17 118-122 (2007)
  42. A screening cascade to identify ERβ ligands. Filgueira CS, Benod C, Lou X, Gunamalai PS, Villagomez RA, Strom A, Gustafsson JÅ, Berkenstam AL, Webb P. Nucl Recept Signal 12 e003 (2014)
  43. Targeting estrogen receptor-β for the prevention of nonmelanoma skin cancer. Yao PL, Gonzalez FJ, Peters JM. Cancer Prev Res (Phila) 7 182-185 (2014)
  44. Design and synthesis of carborane-containing estrogen receptor-beta (ERβ)-selective ligands. Ohta K, Ogawa T, Oda A, Kaise A, Endo Y. Bioorg Med Chem Lett 25 4174-4178 (2015)
  45. Role of pocket flexibility in the modulation of estrogen receptor alpha by key residue arginine 394. Mu Y, Peng S, Zhang A, Wang L. Environ Toxicol Chem 30 330-336 (2011)
  46. Synthesis and structure-activity relationships of 1-benzylindane derivatives as selective agonists for estrogen receptor beta. Yonekubo S, Fushimi N, Miyagi T, Nakanishi O, Katsuno K, Ozawa M, Handa C, Furuya N, Muranaka H. Bioorg Med Chem 24 5895-5910 (2016)
  47. Human Estrogen Receptor Alpha Antagonists, Part 3: 3-D Pharmacophore and 3-D QSAR Guided Brefeldin A Hit-to-Lead Optimization toward New Breast Cancer Suppressants. Kurtanović N, Tomašević N, Matić S, Proia E, Sabatino M, Antonini L, Mladenović M, Ragno R. Molecules 27 2823 (2022)
  48. Protein-structure-based prediction of animal model suitability for pharmacodynamic studies of subtype-selective estrogens. Toschi L, Hilbig J, Wintermantel T, Engelhaupt A, Walter A, Fritzemeier KH, Hillisch A. ChemMedChem 1 1237-1248 (2006)
  49. Towards β-selectivity in functional estrogen receptor antagonists. Rodríguez JJ, Filipiak K, Maslyk M, Ciepielski J, Demkowicz S, de Pascual-Teresa S, Martín-Santamaría S, de Pascual-Teresa B, Ramos A. Org Biomol Chem 10 7334-7346 (2012)
  50. Descriptor analysis of estrogen receptor β-selective ligands using 2-phenylquinoline, tetrahydrofluorenone and 3-hydroxy 6H-benzo[c]chromen-6-one scaffolds. Balaji, Muthiah R, Sabarinath, Ramamurthy, Chandrasekharan. J Enzyme Inhib Med Chem 26 831-842 (2011)
  51. Indole Derivative Interacts with Estrogen Receptor Beta and Inhibits Human Ovarian Cancer Cell Growth. Verardi L, Fiori J, Andrisano V, Locatelli A, Morigi R, Naldi M, Bertucci C, Strocchi E, Boga C, Micheletti G, Calonghi N. Molecules 25 E4438 (2020)
  52. Noteworthy effect of slight variation in aliphatic chain length of trisubstituted imidazole inhibitors against epidermal growth factor receptor L858R/T790M/C797S mutant in cancer therapy. Akher FB, Farrokhzadeh A, Soliman MES. Chem Biol Drug Des 93 798-810 (2019)
  53. One-step synthesis of azole- and benzazole-based sulfonamides in aqueous media. Zali-Boeini H, Najafi Z, Abtahi B, Ghaleshahi HG. Mol Divers 19 283-292 (2015)
  54. Enhancement of Female Rat Fertility via Ethanolic Extract from Nigella sativa L. (Black Cumin) Seeds Assessed via HPLC-ESI-MS/MS and Molecular Docking. Nagy AM, Abdelhameed MF, Elkarim ASA, Sarker TC, Abd-ElGawad AM, Elshamy AI, Hammam AM. Molecules 29 735 (2024)
  55. Synthesis and evaluation of 17α-triazolyl and 9α-cyano derivatives of estradiol. Wetzel EA, Hanson AM, Troutfetter CL, Burkett DJ, Sem DS, Donaldson WA. Bioorg Med Chem 28 115670 (2020)


Quick links